ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

CVS vs YI // EV/EBITDA & P/E VALUATION

CVS Health Corporation (NYSE) VS. 111 Inc. (NASDAQ) • 15-METRIC TALLY: CVS 8 — YI 1
■ METRIC PARITY
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (CVS VS. YI) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC CVS YI SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin 45.00% 5.80% +39.20 CVS /gross-margins <GO>
Return on Invested Capital (ROIC) 2.60% -20.50% +23.10 CVS /roic <GO>
EV/EBITDA & P/E Valuation ACTIVE 25.7x — — TIE /valuation <GO>
Free Cash Flow Yield 6.76% — — TIE /fcf-yield <GO>
Operating Margin 1.20% 0.00% +1.20 CVS /operating-margins <GO>
Net Profit Margin 0.40% — — TIE /net-margins <GO>
Revenue Growth (YoY) 7.80% -9.00% +16.80 CVS /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 2.94% 0.00% +2.94 CVS /dividend-safety <GO>
Altman Z-Score & Debt/Equity 2.31 3.34 -1.03 YI /balance-sheet <GO>
Piotroski F-Score Quality 7/9 3/9 +4.00 CVS /piotroski-score <GO>
Options Implied Move & Put/Call Skew — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum 47.8 32.8 +14.97 CVS /rsi-technicals <GO>
10Y Yield & FRED Macro Beta 0.88 — — TIE /macro-sensitivity <GO>
Forward P/E Multiple 60.7x — — TIE /forward-pe <GO>
Enterprise Scale & Market Cap $115.53B $26.2M $115.50B CVS /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR CVS REV YI REV CVS GROSS % YI GROSS % CVS FCF YI FCF
FY 2025 $402.07B $1.80B 45.0% 5.8% $7.81B $16.4M
FY 2024 $372.81B $1.97B 44.7% 5.8% $6.33B $34.0M
FY 2023 $357.78B $2.11B — — -$2.67B -$63.0M
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
CVS // BETA 0.88
YI // BETA —